[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$130share

J&J's oncology franchise shows strong performance with high PFS rates, while LRN is considered undervalued despite recent revenue guidance concerns. PRSO is poised for a breakout, with execs urged to consider a deal.

About $130share

This topic analyzes financial news and stock market performance, focusing on specific stock price points and significant market achievements.

Insights

• $130share engagements is up XXXXX% from the previous month.

Engagements: XX (24h)

Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXXXX
X Week: XX +64%
X Month: XXXXXX +930%
X Months: XXXXXXX -XX%
X Year: XXXXXXX +200%
1-Year High: XXXXXXX on 2025-03-28
1-Year Low: X on 2025-01-17

Engagements by network (24h): X: XX

Mentions: X (24h)

Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
X Week: X no change
X Month: XX +5.60%
X Months: XX +22%
X Year: XXX +72%
1-Year High: XX on 2025-04-16
1-Year Low: X on 2024-12-16

Mentions by network (24h): X: XX

Creators: X (24h)

Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $130share in the last XX hours which is up XXX% from X in the previous XX hours Daily Average: X
X Week: X no change
X Month: XX -XX%
X Months: XX +35%
X Year: XXX +61%
1-Year High: XX on 2025-04-15
1-Year Low: X on 2024-12-16

Top $130share Social Posts

Top posts by engagements in the last XX hours

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"J&J Breaking News: Game-Changing Multiple Myeloma Data 🚨 High PFS rates support shifting this regimen to frontline therapy Bolsters J&J's oncology powerhouse Darzalex/Tecvayli franchise Plus Q4 dividend of $1.30/share paid today steady income stream intact Thoughts"
X Link @OvidiuCD 2025-12-10T07:49Z X followers, XX engagements

"$LRN - reiterate: Undervalued. Our GAAP DCF now sits at around $130/share largely downgraded from the previous coverage of this stock but we view the recent stock price drop after earnings as a major over-reaction to revenue guidance being underwhelming"
X Link @lucisafferens 2025-12-09T16:02Z XX followers, XX engagements

"$PRSO is about to have a major breakout to cover the gap finally. for $1.30/share prso execs need to give $MOBX leaders the finger"
X Link @ShadowTrader17 2025-10-09T20:25Z XXX followers, XXX engagements